Mark Alan Goldberg, SVP, Product Development at SYNAGEVA BIOPHARMA CORP (GEVA), sold 4,417 shares at $47.52 ($210K) on 2013-01-02, disclosed to the SEC on 2013-01-04.
Scheduled sale ($210k) by SVP, Product Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| BPMC | SELL | 2020-12-22 | $654K | — | Filing → |
| BPMC | SELL | 2020-12-15 | $627K | — | Filing → |
| BPMC | SELL | 2020-12-03 | $600K | — | Filing → |